Key Highlights
- On March 25, Chief Global Commercialization Officer Anthony Mancini offloaded 26,552 shares valued at approximately $3.5M through a predetermined 10b5-1 trading arrangement
- Shares began Wednesday’s session at $94.29, retreating 1.3%, within a 52-week trading band of $29.17 to $124.49
- On March 26, Truist Financial elevated RVMD to a “strong-buy” designation, aligning with optimistic calls from Jefferies, Evercore, UBS, and Wedbush
- Company insiders have divested approximately 149,592 shares (totaling roughly $15M) during the last three months, yet institutional stakeholders maintain 94.34% ownership
- Fourth quarter 2025 earnings per share registered at -$1.86, falling short of the -$1.56 analyst projection, primarily due to elevated research and development alongside selling, general, and administrative expenditures
Shares of Revolution Medicines (RVMD) began trading at $94.29 on Wednesday, March 26, reflecting a 1.3% decline from the previous session.
Revolution Medicines, Inc., RVMD
On March 25, the biotech firm’s Chief Global Commercialization Officer, Anthony Mancini, executed a sale of 26,552 shares generating proceeds of roughly $3.5 million. The divestiture occurred across a price spectrum ranging from $93.22 to $97.21 per share.
These transactions took place pursuant to a Rule 10b5-1 trading arrangement that Mancini established on December 24, 2025. Such automated plans allow executives to schedule stock transactions in advance, suggesting the sales don’t inherently reflect current sentiment about the company’s prospects.
Concurrently, Mancini exercised stock options to purchase 37,450 shares at a strike price of $33.62 each, amounting to approximately $1.26 million. Following these combined activities, his direct holdings now comprise 54,400 shares plus an additional 54,400 restricted stock units.
Mancini’s activity represents part of a broader pattern of insider transactions. Mark A. Goldsmith, another company insider, disposed of 12,871 shares on March 17 at an average selling price of $99.48, generating proceeds exceeding $1.28 million. That same trading day, Chief Financial Officer Jack Anders offloaded 2,753 shares at the identical price point, netting approximately $274,000.
Cumulatively, company insiders have liquidated roughly 149,592 shares valued at $15 million throughout the preceding 90-day period. Current insider ownership represents 8.20% of outstanding shares.
Wall Street Firms Issue Strong-Buy Recommendation
Contrary to the insider selling trend, Wall Street’s research community maintains predominantly optimistic coverage. Truist Financial elevated its rating on RVMD to “strong-buy” on March 26.
Evercore issued an identical recommendation earlier on February 25. Jefferies launched coverage with a “buy” rating on March 16. UBS also initiated research with a “buy” stance on February 27.
Weiss Ratings stands as the solitary bearish voice, maintaining a “sell (d-)” assessment. MarketBeat’s aggregated consensus registers as “Buy,” though the average price objective of $78.94 remains considerably beneath current trading levels.
Individual firm projections prove more ambitious. Piper Sandler elevated its price target to $120 (Overweight designation), Wells Fargo established a $144 objective, and Needham positions its target at $145 accompanied by a Buy rating.
Institutional Capital Inflows Continue Despite Quarterly Shortfall
On the institutional investment front, capital allocation has accelerated noticeably. Norges Bank established a fresh position valued at approximately $195.6 million during Q4. Avoro Capital initiated holdings worth roughly $172.8 million. UBS expanded its stake by 183.6% to reach 3,087,937 shares, representing a position valued near $246 million. Polar Capital amplified its holdings by 321.2%, now controlling more than 2 million shares.
Institutional investment firms collectively control 94.34% of RVMD shares.
This bullish institutional positioning persists despite the company’s fourth quarter 2025 earnings disappointment. The biopharmaceutical company recorded a loss of $1.86 per share, compared against Wall Street’s consensus forecast of -$1.56, representing a $0.30 variance. Management attributed the shortfall to research and development investments and selling, general, and administrative costs exceeding initial projections.
Revenue generation wasn’t problematic — the organization concluded the quarter maintaining $2.03 billion in cash reserves and investment holdings, bolstered partially through an agreement with Royalty Pharma. Wall Street analysts currently forecast a full fiscal year 2026 earnings per share of -$3.49.
RVMD trades with a 50-day moving average of $101.53 and a 200-day moving average of $78.24. The company’s market capitalization stands at $18.69 billion.
Throughout the past twelve months, RVMD has climbed 145%. During the most recent six-month period, shares have appreciated 112%.
